Company: PCRX
Filing Date: 2025-03-14
Form Type: DEFA14A
Source: 0001104659-25-024033
Chunk: 8

Company: Pacira BioSciences, Inc.
Filing Date: 2025-03-14
Form: DEFA14A
Chunk 8
---
, such as the risk that the acquired businesses will not be integrated successfully, that such integration may be more
difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; Pacira’s
manufacturing and supply chain, global and U.S. economic conditions (including inflation and rising interest rates), and
Pacira’s business, including Pacira’s revenues, financial condition, cash flow and results of operations; the success of
Pacira’s sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate
and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL,
ZILRETTA and iovera° and Pacira’s ability to serve those markets; Pacira’s plans to expand the use of EXPAREL,
ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for
EXPAREL, ZILRETTA and iovera°; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of
U.S. Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and
success of European Medicines Agency Marketing Authorization Applications; Pacira’s plans to evaluate, develop and pursue
additional product candidates utilizing Pacira’s proprietary multivesicular liposome (“pMVL”) drug delivery
technology; the approval of the commercialization of Pacira’s products in other jurisdictions; clinical trials in support of
an existing or potential pMVL-based product; Pacira’s commercialization and marketing capabilities; Pacira’s ability to
successfully complete capital projects; the outcome of any litigation; the recoverability of Pacira’s deferred tax assets;
assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with
determining the fair value of the Company; the anticipated funding or benefits of Pacira’s share repurchase program; and
factors discussed in the “Risk Factors” of Pacira’s most recent Annual Report on Form 10-K and in other filings
that it periodically makes with the SEC. In addition, the forward-looking statements included in this document represent
Pacira’s views as of the date of this document. Important factors could cause